Subsequently, NASH-HCC murine model was established using DUSP22HepKO, FAKHepKO, and Hep-DKO mice to investigate the effects of FAK activation on DUSP22-mediated NASH-HCC progression. This evidence concerns the gene PTK2 and hepatocellular carcinoma.